RecruitingNCT03718923

FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

The Seaver Autism Center for Research and Treatment - Assessment Core

Sponsor

Icahn School of Medicine at Mount Sinai

Enrollment

50 participants

Start Date

Mar 28, 2016

Study Type

OBSERVATIONAL

Conditions

Autism Spectrum Disorder FOXP1 Mental Retardation With Language Impairment and With or Without Autistic Features

Summary

FOXP1, also known as Forkhead-box Protein P1, is a transcription factor protein belonging to the FOX gene family. Disruptions in the FOXP1 gene cause a phenotype characterized by global developmental delay, speech deficits, mild dysmorphic features, and traits of autism spectrum disorder. This study seeks to characterize FOXP1-related neurodevelopmental disorders using a number of genetic, medical and neuropsychological measures.

Eligibility

Min Age: 2 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with autism spectrum disorder, foxp1, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.